FDA Approves Roche's Wilserdly for ESR1-Mutated Breast Cancer

The FDA has approved Roche's Wilserdly (giredestrant) in combination with everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease recurred during or after endocrine-based adjuvant therapy or progressed on at least one endocrine-based regimen in the metastatic setting.

Approval is supported by the evERA Breast Cancer study, a randomized, open-label, multicenter Phase 3 trial comparing Wilserdly plus everolimus with standard endocrine therapy plus everolimus in patients previously treated with a CDK4/6 inhibitor and endocrine therapy. In patients with ESR1-mutated disease progressing after CDK4/6 inhibitor therapy, the all-oral combination significantly prolonged progression-free survival, reducing the risk of disease progression or death by 62% versus standard endocrine therapy plus everolimus (stratified hazard ratio 0.38; p<0.0001).

Up to 40% of patients with hormone receptor-positive metastatic breast cancer develop ESR1 mutations, which are considered the primary cause of hormone therapy resistance and drive disease progression. Roche said the combination targets two different signaling pathways, pairing estrogen receptor degradation with mTOR inhibition, while remaining an oral regimen without injections.

Roche has also submitted a New Drug Application for Wilserdly as adjuvant treatment for adults with ER-positive, HER2-negative, stage I-III breast cancer at intermediate to high risk of recurrence, based on the Phase 3 lidERA study, which is under Priority Review with a November 30, 2026 action date. If approved, it would be the first new adjuvant endocrine therapy in more than 20 years, according to Roche.

The evERA results were published in the New England Journal of Medicine, and Roche is pursuing additional regulatory filings outside the US, with six company-sponsored Phase 3 trials underway across multiple treatment settings and lines of therapy.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!

Sign up now!

  • <<
  • >>

Join the Discussion